Capuano et al. evaluated cases of subclinical CNV in eyes with geographic atrophy finding a lower mean atrophy rate compared to the reported rates in all eyes with geographic atrophy.[7] This group warned against treating subclinical CNV with anti-VEGF until conversion to exudative AMD. The gene discussed is VEGFA; the disease is atrophic macular degeneration.